[go: up one dir, main page]

MY196072A - Liquid Inhalation Formulation Comprising RPL554 - Google Patents

Liquid Inhalation Formulation Comprising RPL554

Info

Publication number
MY196072A
MY196072A MYPI2017000391A MYPI2017000391A MY196072A MY 196072 A MY196072 A MY 196072A MY PI2017000391 A MYPI2017000391 A MY PI2017000391A MY PI2017000391 A MYPI2017000391 A MY PI2017000391A MY 196072 A MY196072 A MY 196072A
Authority
MY
Malaysia
Prior art keywords
rpl554
inhalation formulation
liquid inhalation
pharmaceutical composition
liquid pharmaceutical
Prior art date
Application number
MYPI2017000391A
Inventor
Peter Lionel Spargo
Edward James French
Phillip A Haywood
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1416274.7A external-priority patent/GB201416274D0/en
Priority claimed from GBGB1504662.6A external-priority patent/GB201504662D0/en
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of MY196072A publication Critical patent/MY196072A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9, 10-- dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7- tetrahydro-2H-pyrimido[6,1-a]isoqui nolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body. [Figure 1]
MYPI2017000391A 2014-09-15 2015-09-15 Liquid Inhalation Formulation Comprising RPL554 MY196072A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1416274.7A GB201416274D0 (en) 2014-09-15 2014-09-15 Formulation
GBGB1504662.6A GB201504662D0 (en) 2015-03-19 2015-03-19 Formulation
PCT/GB2015/052668 WO2016042313A1 (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554

Publications (1)

Publication Number Publication Date
MY196072A true MY196072A (en) 2023-03-13

Family

ID=54196992

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017000391A MY196072A (en) 2014-09-15 2015-09-15 Liquid Inhalation Formulation Comprising RPL554

Country Status (27)

Country Link
US (2) US9956171B2 (en)
EP (3) EP3332767B1 (en)
JP (2) JP6860477B2 (en)
KR (1) KR102379309B1 (en)
CN (3) CN111249260B (en)
AU (3) AU2015316592B2 (en)
CA (1) CA2959943C (en)
CY (3) CY1120264T1 (en)
DK (3) DK3494962T3 (en)
ES (3) ES2730810T3 (en)
HK (1) HK1249415B (en)
HR (3) HRP20180833T1 (en)
HU (3) HUE045303T2 (en)
IL (1) IL250895B (en)
LT (3) LT3193835T (en)
MX (1) MX2017003102A (en)
MY (1) MY196072A (en)
NO (1) NO3193835T3 (en)
PH (1) PH12017500479B1 (en)
PL (3) PL3332767T3 (en)
PT (3) PT3193835T (en)
RS (3) RS58897B1 (en)
RU (1) RU2699995C2 (en)
SG (1) SG11201701854WA (en)
SI (3) SI3193835T1 (en)
SM (3) SMT201800242T1 (en)
WO (1) WO2016042313A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3231444T1 (en) 2014-05-12 2020-04-30 Verona Pharma Plc New treatment
DK3494962T3 (en) * 2014-09-15 2021-06-21 Verona Pharma Plc Liquid inhalation formulation comprising RPL554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
HK1251593A1 (en) 2015-07-24 2019-02-01 豪夫迈‧罗氏有限公司 Bace1 inhibitor peptides
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
JP6994061B2 (en) * 2019-02-15 2022-01-14 ノバルティス アーゲー Preparation of 4- (7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3-yl) -benzonitrile
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
ES2995084T3 (en) * 2020-01-15 2025-02-05 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pharmaceutical composition of tricyclic pde3/pde4 dual inhibitor compound
GB202002786D0 (en) * 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB202202297D0 (en) * 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
KR20250048092A (en) * 2022-08-08 2025-04-07 베로나 파마 피엘씨 Ensifenthrine (RPL-554) for reducing the frequency and/or severity of exacerbations in chronic obstructive pulmonary disease
WO2024033627A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Plc Liquid pharmaceutical composition
JP2025534762A (en) * 2022-10-28 2025-10-17 江蘇恒瑞医薬股▲ふん▼有限公司 Pharmaceutical compositions containing isoquinolinone compounds and methods for preparing the same
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
TW202506117A (en) 2023-06-26 2025-02-16 英商維羅納製藥Ｐｌｃ公司 Particulate composition
US20250073240A1 (en) * 2023-09-06 2025-03-06 Verona Pharma Plc New treatment
WO2025168546A1 (en) * 2024-02-05 2025-08-14 Verona Pharma Plc Ensifentrine for the treatment of copd
WO2025168706A1 (en) * 2024-02-07 2025-08-14 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
US20250249008A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
JP3676674B2 (en) * 1997-10-09 2005-07-27 シェーリング コーポレイション Mometasone furoate suspension for spraying
SE9704186D0 (en) 1997-11-14 1997-11-14 Astra Ab New composition of matter
EP1165558B1 (en) 1999-03-31 2003-09-24 Vernalis Limited Derivatives of pyrimido[6,1-a]isoquinolin-4-one
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0122031D0 (en) 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
RU2440972C2 (en) * 2004-12-17 2012-01-27 Сипла Лимитед Crystalline levosalbutamol sulfate, method of its obtaining and pharmaceutical composition, which contains it
ITMI20051999A1 (en) 2005-10-21 2007-04-22 Eratech S R L INHALATION FORMULATIONS OF DRUGS IN DRY POWDER FOR ADMINISTRATION AS SUCH OR WITH NEBULIZER AND EQUIPPED WITH HIGH EROGABILITY RESPIRABILITY AND STABILITY
KR20130087405A (en) * 2010-06-22 2013-08-06 키에시 파르마슈티시 엣스. 피. 에이. Alkaloid aminoester derivatives and medicinal compositions thereof
PH12013500261A1 (en) * 2010-08-09 2013-03-04 Verona Pharma Plc Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (en) * 2011-06-07 2014-11-12 Parion Sciences Inc Methods of treatment
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2014037727A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Carcainium salts
PT2968313T (en) * 2013-03-15 2018-02-21 Verona Pharma Plc Drug combination
CN106105056B (en) * 2014-03-11 2019-07-12 Lg电子株式会社 Method and device for sending discovery signal by D2D user equipment in communication system
SI3231444T1 (en) 2014-05-12 2020-04-30 Verona Pharma Plc New treatment
DK3494962T3 (en) * 2014-09-15 2021-06-21 Verona Pharma Plc Liquid inhalation formulation comprising RPL554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
DK3494962T3 (en) 2021-06-21
NO3193835T3 (en) 2018-08-04
EP3332767B1 (en) 2019-03-20
EP3193835B1 (en) 2018-03-07
RS58897B1 (en) 2019-08-30
RS62252B1 (en) 2021-09-30
CN106794157A (en) 2017-05-31
SMT202100479T1 (en) 2021-09-14
PT3332767T (en) 2019-06-27
AU2015316592A1 (en) 2017-03-23
EP3494962B1 (en) 2021-05-26
PL3193835T3 (en) 2018-07-31
PH12017500479A1 (en) 2017-07-31
ES2875584T3 (en) 2021-11-10
ES2670025T3 (en) 2018-05-29
PH12017500479B1 (en) 2021-07-21
CY1121698T1 (en) 2020-07-31
SI3193835T1 (en) 2018-06-29
PL3494962T3 (en) 2021-12-06
US9956171B2 (en) 2018-05-01
SI3332767T1 (en) 2019-07-31
LT3332767T (en) 2019-06-25
EP3193835A1 (en) 2017-07-26
DK3332767T3 (en) 2019-06-24
BR112017005050A2 (en) 2018-01-23
JP6860477B2 (en) 2021-04-14
IL250895A0 (en) 2017-04-30
JP2017528479A (en) 2017-09-28
HRP20180833T1 (en) 2018-06-29
NZ767295A (en) 2024-01-26
AU2018286571A1 (en) 2019-01-24
CN111249260A (en) 2020-06-09
PT3193835T (en) 2018-03-27
CY1120264T1 (en) 2019-07-10
EP3332767A1 (en) 2018-06-13
AU2020203081B2 (en) 2021-08-05
US20170239178A1 (en) 2017-08-24
KR20170054406A (en) 2017-05-17
LT3494962T (en) 2021-07-26
US20180369139A1 (en) 2018-12-27
AU2015316592B2 (en) 2020-04-02
KR102379309B1 (en) 2022-03-28
HUE045303T2 (en) 2019-12-30
LT3193835T (en) 2018-06-11
CN110051627A (en) 2019-07-26
CA2959943A1 (en) 2016-03-24
RS57227B1 (en) 2018-07-31
IL250895B (en) 2019-08-29
CN111249260B (en) 2023-01-10
NZ767296A (en) 2024-01-26
ES2730810T3 (en) 2019-11-12
EP3494962A1 (en) 2019-06-12
HRP20191122T1 (en) 2019-09-20
CY1124546T1 (en) 2022-07-22
SI3494962T1 (en) 2021-09-30
NZ729796A (en) 2024-01-26
JP6795574B2 (en) 2020-12-02
JP2019069978A (en) 2019-05-09
RU2699995C2 (en) 2019-09-12
RU2017108432A3 (en) 2019-04-01
SMT201900340T1 (en) 2019-07-11
DK3193835T3 (en) 2018-05-07
SG11201701854WA (en) 2017-04-27
CN106794157B (en) 2021-03-09
PT3494962T (en) 2021-06-22
PL3332767T3 (en) 2019-10-31
HUE038433T2 (en) 2018-10-29
RU2017108432A (en) 2018-10-17
SMT201800242T1 (en) 2018-07-17
MX2017003102A (en) 2017-06-14
US10945950B2 (en) 2021-03-16
HK1249415B (en) 2019-11-22
HUE055527T2 (en) 2021-12-28
AU2020203081A1 (en) 2020-05-28
CA2959943C (en) 2022-08-16
HRP20211035T1 (en) 2021-09-17
AU2018286571B2 (en) 2020-04-02
WO2016042313A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
PH12017500479A1 (en) Liquid inhalation formulation comprising prl554
MX2021004110A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n' -(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl] ethane-1,2-diamine.
MY199968A (en) Formulations of an lsd1 inhibitor
PH12016500433B1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
SG10201902598VA (en) Peptidomimetic macrocycles and formulations thereof
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
HK1217092A1 (en) Therapeutic compounds and uses thereof
SG10201906400SA (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MY196333A (en) Intranasal Composition Comprising Betahistine
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
MX2017004633A (en) Formulations containing tiotropium, amino acid and acid and methods thereof.
PH12018502195A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
TH174318A (en) Formula
WO2018084817A3 (en) A new form of active agent
HK1233927A1 (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
HK1231763A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
HK1254670A1 (en) Triptan powders for pulmonary delivery
HK1217191A1 (en) Therapeutic compounds and uses thereof